ADD ANI AS A TRUSTED SOURCE
googleads
Menu
Business

"LOPIKAST: A drug to fight against coronavirus"

New Delhi [India] Feb 8 (ANI/NewsVoir): The endemic of coronavirus started from Wuhan city of China and is knocking at the doors of different countries of the world.

ANI Feb 08, 2020 13:01 IST googleads

Lopinavir & Ritonavir

New Delhi [India] Feb 8 (ANI/NewsVoir): The endemic of coronavirus started from Wuhan city of China and is knocking at the doors of different countries of the world.
The deadly symptoms of coronavirus have put many lives at risk in various regions of the world with maximum effect in Asia, especially in China.
Continuous attempts are been made to find a cure for this virus, however, considering the growing number of cases, doctors have decided to look for some unconventional remedies.
A drug developed to cure HIV infections is used in the treatment of coronavirus cases. Two antiretroviral components, Lopinavir and Ritonavir, are protease inhibitors designed to block HIV viral replication.
One hypothesis holds that the drugs could do the same with 2019-nCoV (Coronavirus), which is believed to have originated from the Chinese city of Wuhan.
LOPIKAST is a generic version of Kaletra, now recommended as a treatment for pneumonia caused by the new coronavirus known as 2019-nCoV, China's National Health Commission said in its updated clinical guidance.
Wang Guangfa, the leader of Peking University First Hospital's pulmonary and critical care medicine department, contracted the virus as a member of a national expert team dispatched to Wuhan.
Lopinavir & Ritonavir tablets killed his disease, Wang told state-run China News Service in a report (Chinese) on Thursday.
In India, Aprazer Healthcare Private Limited is a pharmaceutical company, based in Delhi, which is continuously evolving by providing lifesaving drugs at affordable prices.
Aprazer Healthcare Private Limited markets LOPIKAST having the composition of Ritonavir 50 mg and Lopinavir 200 mg.
As this drug is recommended to use in coronavirus cases, the company has started exporting the product to China and other flu-prone regions at economical prices.
The company offers reduced prices of this life-saving drug so that it is easily accessible. "At Aprazer, our endeavour is to contribute by supplying the LOPIKAST tablets at the all-time low prices", said CEO of the Company Aprazer announcing the measures taken by Aprazer Healthcare Pvt Ltd.
"This drug at cost-effective prices will prove to be a stronger response to the prevailing crisis. As it's a global emergency, we have to face it together", he added
"If a person is suffering from the expected symptoms of coronavirus, he/she must visit the doctor immediately. Lopikast shouldn't be taken without recommendation and prescription of Physician", explained the CEO, Aprazer.
According to the doctors treating infected patients of coronavirus, the medicine is not a complete cure for the ailment. However, after taking the medicine, in combination with flu drug and HIV drug to an infected person, the symptoms are expected to improve considerably.
Aprazer Healthcare Pvt Ltd has already begun to supply LOPIKAST tablets in the hospitals and cure centers across China.
Coronavirus outbreak in China is screaming for assistance from all over the world. The sensitive approach of Aprazer's is what other corporations should replicate because as rightly quoted by Gandhi 'Sometimes profit is not a consideration'.
This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article. (ANI/NewsVoir)

Get the App

What to Read Next

Business

O2h Group Hosts the 8th O2h Collaborative Innovation Conference

O2h Group Hosts the 8th O2h Collaborative Innovation Conference

Ahmedabad (Gujarat) [India], March 12: The 8th edition of the o2h Collaborative Innovation Conference concluded in Ahmedabad, bringing together an eclectic gathering of entrepreneurs, scientists, venture investors, policymakers and changemakers for a day of dialogue, debate and shared curiosity.

Read More
Business

Paperpal for Life Sciences Establishes HIPAA Readiness

Paperpal for Life Sciences Establishes HIPAA Readiness

Mumbai (Maharashtra) [India], March 10: Paperpal for Life Sciences, an enterprise-grade Artificial Intelligence (AI) platform by Cactus Communications, purpose-built for Medical Affairs and Life Sciences organizations, announced the completion of an assessment evaluating its operational and technical safeguards to support Health Insurance Portability and Accountability Act (HIPAA) requirements. This milestone reinforces Paperpal's commitment to meeting the rigorous standards of security, data protection, and regulatory readiness required for regulated scientific workflows.

Read More
Business

Avery Pharmaceuticals Show Innovative Nutraceutical Products

Avery Pharmaceuticals Show Innovative Nutraceutical Products

Mumbai (Maharashtra) [India], February 27: Avery Pharmaceuticals Pvt. Ltd. showcased its innovative Mouth Dissolving Strips and CDMO solutions at Vitafoods India 2026, held from February 11-13 at the Jio World Convention Centre in Mumbai. Over 500 visitors engaged with our booth, showcasing the robust interest from key players across the pharmaceutical, nutraceutical, and healthcare sectors. . The participation enabled the company to demonstrate its scientific capabilities, initiate new business conversations, and strengthen relationships with existing and prospective partners.

Read More
Business

India’s Wireless Lighting Pioneer Rosha plans to scale Globally

India’s Wireless Lighting Pioneer Rosha plans to scale Globally

New Delhi [India], February 25: Rosha, India's first wireless, portable and rechargeable lighting-focused brand, is expanding globally. Founded in 2019, by three school friends -- Gaurav, Kanwar and Shivam -- the company was born from a simple yet pressing challenge observed across the hospitality industry: high recurring expenditure on candles, safety concerns, and the inconvenience of wired lighting solutions. In a short span of six years, the company is helping redefine ambience creation across restaurants, hotels and modern homes in India and abroad.

Read More
Business

India healthcare sector growth to strengthen over next 3 years

India healthcare sector growth to strengthen over next 3 years

The domestic healthcare sector is expected to see stronger growth over the next three years supported by new drug launches, while earnings from the US generics business are likely to remain flat for most companies, according to a report by Systematix Research.

Read More
Home About Us Our Products Advertise Contact Us Terms & Condition Privacy Policy

Copyright © aninews.in | All Rights Reserved.